Dicerna Pharmaceuticals Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dicerna Pharmaceuticals stock.
View analyst ratings for Dicerna Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Dicerna Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Dicerna Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its earnings results on Thursday, February, 25th. The biopharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by $0.60. Dicerna Pharmaceuticals had a negative net margin of 88.81% and a negative trailing twelve-month return on equity of 71.72%.
View Dicerna Pharmaceuticals' earnings history.

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, DRNA stock has increased by 74.8% and is now trading at $29.51.
View which stocks have been most impacted by COVID-19.

8 analysts have issued 12 month target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $33.00 to $45.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $37.13 in the next year. This suggests a possible upside of 25.8% from the stock's current price.
View analysts' price targets for Dicerna Pharmaceuticals or view top-rated stocks among Wall Street analysts.

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Dicerna Pharmaceuticals include Arrowhead Pharmaceuticals (ARWR), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), United Therapeutics (UTHR), Schrödinger (SDGR), Sarepta Therapeutics (SRPT), GW Pharmaceuticals (GWPH), Evotec (EVTCY), Allakos (ALLK), Atea Pharmaceuticals (AVIR), Maravai LifeSciences (MRVI), TG Therapeutics (TGTX), Perrigo (PRGO) and Blueprint Medicines (BPMC).
View all of DRNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (8.04%), Price T Rowe Associates Inc. MD (2.76%), Candriam Luxembourg S.C.A. (1.88%), Northern Trust Corp (1.11%), JPMorgan Chase & Co. (1.07%) and Renaissance Technologies LLC (0.92%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, Peter Kolchinsky and Regina M Paglia.
View institutional ownership trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Russell Investments Group Ltd., Squarepoint Ops LLC, First Trust Advisors LP, ClariVest Asset Management LLC, Jane Street Group LLC, Price T Rowe Associates Inc. MD, and State of New Jersey Common Pension Fund D. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bob D Brown, James B Weissman, John B Green, and Regina M Paglia.
View insider buying and selling activity for Dicerna Pharmaceuticals or view top insider-selling stocks.

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Caas Capital Management LP, BlackRock Inc., Panagora Asset Management Inc., Silverarc Capital Management LLC, JPMorgan Chase & Co., Candriam Luxembourg S.C.A., Emerald Mutual Fund Advisers Trust, and Emerald Advisers LLC.
View insider buying and selling activity for Dicerna Pharmaceuticals or or view top insider-buying stocks.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRNA stock can currently be purchased for approximately $29.51.

Dicerna Pharmaceuticals has a market capitalization of $2.21 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis.

Dicerna Pharmaceuticals employs 187 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]